Your browser doesn't support javascript.
loading
The effects of provider-prescribed obesogenic drugs on post-laparoscopic sleeve gastrectomy outcomes: a retrospective cohort study.
Leggett, Cecilia B; Desalermos, Athanasios; Brown, Steven D; Lee, Euyhyun; Proudfoot, James A; Horgan, Santiago; Gupta, Samir; Grunvald, Eduardo; Ho, Samuel B; Zarrinpar, Amir.
  • Leggett CB; School of Medicine, University of California, San Diego, CA, USA.
  • Desalermos A; School of Medicine, University of California, San Diego, CA, USA.
  • Brown SD; Division of Gastroenterology, University of California, San Diego, CA, USA.
  • Lee E; School of Medicine, University of California, San Diego, CA, USA.
  • Proudfoot JA; Division of Gastroenterology, University of California, San Diego, CA, USA.
  • Horgan S; Clinical and Translational Research Institute, University of California, San Diego, CA, USA.
  • Gupta S; Clinical and Translational Research Institute, University of California, San Diego, CA, USA.
  • Grunvald E; Clinical and Translational Research Institute, University of California, San Diego, CA, USA.
  • Ho SB; School of Medicine, University of California, San Diego, CA, USA.
  • Zarrinpar A; Department of Surgery, University of California, San Diego, CA, USA.
Int J Obes (Lond) ; 43(6): 1154-1163, 2019 06.
Article en En | MEDLINE | ID: mdl-30242239
ABSTRACT

BACKGROUND:

Laparoscopic sleeve gastrectomy (LSG) is one of the most commonly performed bariatric procedures and has proven effective in providing weight loss. However, considerable variance has been noted in the degree of weight loss. Physician prescription practices may be negatively affecting weight loss post-LSG and, thus, contributing to the broad range of weight loss outcomes. The aim of our study was to determine whether commonly prescribed obesogenic medications negatively affect weight loss outcomes post-LSG. SUBJECTS/

METHODS:

This single center retrospective cohort study performed at a University hospital included 323 patients (≥18 years) within the University California, San Diego Healthcare System who underwent LSG between 2007 and 2016. We identified a list of 32 commonly prescribed medications that have weight gain as a side effect. We compared the percent excess weight loss (%EWL) of patients divided into two groups based on post-LSG exposure to obesogenic medications. A linear regression model was used to analyze %EWL at 12 months post-LSG while controlling for age, initial body mass index (BMI), and use of leptogenic medications.

RESULTS:

A total of 150 patients (Meds group) were prescribed obesogenic medications within the one-year post-LSG follow up period, whereas 173 patients (Control group) were not prescribed obesogenic medications. The Meds group lost significantly less weight compared to the Control group (%EWL ± SEM at 12 months 53.8 ± 2.4 n = 78, 65.0 ± 2.6, n = 84 respectively, P = 0.002). This difference could not be attributed to differences in age, gender, initial BMI, co-morbidities, or prescription of leptogenic medications between the two groups.

CONCLUSIONS:

The use of provider-prescribed obesogenic medications was associated with worse weight loss outcomes post-LSG. Closer scrutiny of patient medications may be necessary to help improve outcomes of weight loss treatments.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Obesidad Mórbida / Pautas de la Práctica en Medicina / Aumento de Peso / Enfermedad Crónica Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male País como asunto: America do norte Idioma: En Año: 2019 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Obesidad Mórbida / Pautas de la Práctica en Medicina / Aumento de Peso / Enfermedad Crónica Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male País como asunto: America do norte Idioma: En Año: 2019 Tipo del documento: Article